snwv20151013_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported)

October 8, 2015

 

SANUWAVE Health, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

000-52985

20-1176000

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

11475 Great Oaks Way, Suite 150, Alpharetta, Georgia

30022

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code

(678) 581-6843

 

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 7.01               Regulation FD Disclosure

 

On October 8, 2015, SANUWAVE Health, Inc., a Nevada Corporation (the "Company"), provided an update on the Company’s Phase III supplemental clinical trial that used the dermaPACE® for the treatment of diabetic foot ulcers. A copy of the related press release is attached as Exhibit 99.1 to this Form 8-K.

 

The Company hosted a conference call with investors on October 8, 2015 at 9 a.m., Eastern Time, to discuss the dermaPACE clinical trial. A copy of management’s prepared remarks is attached hereto as Exhibit 99.2.

 

The information in this Item 7.01 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01               Financial Statements and Exhibits.

 

(d)     Exhibits.

 

 

Exhibit No.

Description

     
  99.1  

Press release, dated October 8, 2015, issued by SANUWAVE Health, Inc., titled “SANUWAVE Health releases dermaPACE clinical trial top line data and preliminary data analysis results.”

     
  99.2  Management’s prepared remarks for the October 8, 2015, SANUWAVE Health, Inc. conference call to discuss the dermaPACE clinical trial.

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SANUWAVE HEALTH, INC.

 

 

 

 

 

 

 

 

 

Dated: October 13, 2015               

By:

 /s/ Lisa E. Sundstrom 

 

 

Name:

      Lisa E. Sundstrom

 

 

Title:

      Controller and interim Chief Financial Officer

 

  

 
 

 

 

 

EXHIBIT INDEX

 

Exhibit No.

Description

     
99.1   Press release, dated October 8, 2015, issued by SANUWAVE Health, Inc., titled “SANUWAVE Health releases dermaPACE clinical trial top line data and preliminary data analysis results.”
     
99.2   Management’s prepared remarks for the October 8, 2015, SANUWAVE Health, Inc. conference call to discuss the dermaPACE clinical trial.